MedPharm moves into $4M expansion of its North Carolina facility
Expansion increases capacity for the company's topical and transdermal services, as well as dedicated innovation, microbiology and histology laboratories.
MedPharm, experts in topical and transdermal drug delivery, has moved into its newly expanded facility in Durham, North Carolina.
The $4-million expansion has tripled the facility’s footprint to approximately 25,000 sq. ft significantly expanding capacity and supporting MedPharm’s continued commitment to the topical and transdermal market.
Investment into the site was made following increased demand for MedPharm’s topical and transdermal services. The expansion covers pre-formulation and formulation development, in vitro release, in vitro penetration/permeation, tissue culture, analytical/bioanalysis, custom device development and tissue engineering. In addition, the new space will include dedicated innovation, microbiology and histology laboratories.
“We are excited to be able to offer an expanded and unmatched level of services from our facility in the North Carolina Research Triangle Park area”, commented Eugene Ciolfi MedPharm’s President and CEO. “The expanded space has a streamlined workflow that segregates phases of work and makes transition through each project more efficient with complimentary equipment positioned where it’s most needed.”
The new laboratory expands capacity for MedPharm’s proprietary models which de-risk its customers’ development programs as it accommodates automated and high throughput analytical instrumentation to improve turnaround times and elevate the consistent quality of data for clients.
The facility’s unique, dedicated innovation Lab will allow MedPharm to continue its pioneering approach to the development of custom performance testing models to meet unmet customer needs in the topical and transdermal markets. This investment also means that MedPharm can react quickly to solving project-specific problems for its customers and stay at the forefront of the latest scientific breakthroughs and technology.
The expansion will also create over 100 new highly skilled scientific and strategic positions in Research Triangle Park in North Carolina.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance